Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id
PublicationView,CA209978,10.1093/neuonc/noac250,Neuro Oncol,36394567,https://pubmed.ncbi.nlm.nih.gov/36394567,RAGE ablation attenuates glioma progression and enhances tumor immune responses by suppressing galectin-3 expression,2023,"Macrophage, Glioblastoma, Microglia, Brain tumor","Ian Y Zhang, Shunan Liu, Leying Zhang, Rongrui Liang, Qingxiao Fang, Jie Zhao, Lyuzhi Ren, Eric F Medina, Aleksandr Filippov, Kimberley-Jane Bonjoc, Ammar Chaudhry, Mojtaba Dayyani, Andrea H Bild, Behnam Badie",Background: Malignant gliomas consist of heterogeneous cellular components that have adopted multiple overlapping escape mechanisms that overcome both targeted and immune-based therapies. The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily that is activated by diverse proinflammatory ligands present in the tumor microenvironment. Activation of RAGE(Read more on Pubmed),Pending Annotation,Pending Annotation,Pending Annotation,,Restricted Access,36394567
